Chronic Heart Failure Market by Country- 20 Therapies & 3,000 Indications Analyzed

Chronic Heart Failure – Pipeline Review, H1 2014

Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on [email protected] with Chronic Heart Failure Market in subject line and your contact details.

Chronic Heart Failure – Pipeline Review, H1 2014, provides an overview of the Chronic Heart Failure’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Heart Failure Market, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Complete report is spread across 140 pages and available @ http://www.reportsnreports.com/reports/280051-chronic-heart-failure-pipeline-review-h1-2014.html.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Heart Failure
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Heart Failure and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Chronic Heart Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Heart Failure pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Buy a copy of report @ http://www.reportsnreports.com/Purchase.aspx?name=280051.

Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Heart Failure
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Heart Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

List of Tables
Number of Products under Development for Chronic Heart Failure, H1 2014 11
Number of Products under Development for Chronic Heart Failure – Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18

Inquire for Discount @ http://www.reportsnreports.com/contacts/Discount.aspx?name=280051.

Comparative Analysis by Early Stage Development, H1 2014 19
Comparative Analysis by Unknown Stage Development, H1 2014 20
Products under Development by Companies, H1 2014 21
Products under Investigation by Universities/Institutes, H1 2014 22
Chronic Heart Failure – Pipeline by Hospira, Inc., H1 2014 23
Chronic Heart Failure – Pipeline by Sanofi, H1 2014 24
Chronic Heart Failure – Pipeline by Novartis AG, H1 2014 25
Chronic Heart Failure – Pipeline by Laboratoires Pierre Fabre SA, H1 2014 26
Chronic Heart Failure – Pipeline by Les Laboratoires Servier SAS, H1 2014 27
Chronic Heart Failure – Pipeline by Pfizer Inc., H1 2014 28
Chronic Heart Failure – Pipeline by Bayer AG, H1 2014 29
Chronic Heart Failure – Pipeline by Celladon Corporation, H1 2014 30
Chronic Heart Failure – Pipeline by Mesoblast Limited, H1 2014 31
Chronic Heart Failure – Pipeline by Palatin Technologies, Inc., H1 2014 32
Chronic Heart Failure – Pipeline by MetrioPharm AG, H1 2014 33
Chronic Heart Failure – Pipeline by Scynexis, Inc., H1 2014 34
Chronic Heart Failure – Pipeline by t2cure GmbH, H1 2014 35
Chronic Heart Failure – Pipeline by Cyano Biotech GmbH, H1 2014 36
Chronic Heart Failure – Pipeline by NormOxys, Inc., H1 2014 37
Chronic Heart Failure – Pipeline by Cardioxyl Pharmaceuticals, Inc., H1 2014 38
Chronic Heart Failure – Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2014 39
Chronic Heart Failure – Pipeline by miRagen Therapeutics, Inc., H1 2014 40
Chronic Heart Failure – Pipeline by Fibrotech Therapeutics Pty. Ltd., H1 2014 41

Inquiry Before Buying @ http://www.reportsnreports.com/contacts/InquiryBeforeBuy.aspx?name=280051.

Chronic Heart Failure – Pipeline by Otsuka Holdings Co., Ltd., H1 2014 42
Chronic Heart Failure – Pipeline by Provasculon, Inc., H1 2014 43
Chronic Heart Failure – Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2014 44
Assessment by Monotherapy Products, H1 2014 45
Assessment by Combination Products, H1 2014 46
Number of Products by Stage and Target, H1 2014 49
Number of Products by Stage and Mechanism of Action, H1 2014 52
Number of Products by Stage and Route of Administration, H1 2014 54
Number of Products by Stage and Molecule Type, H1 2014 56
Chronic Heart Failure Therapeutics – Recent Pipeline Updates, H1 2014 103
Chronic Heart Failure – Dormant Projects, H1 2014 127

List of Figures
Number of Products under Development for Chronic Heart Failure, H1 2014 11
Number of Products under Development for Chronic Heart Failure – Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13

Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Assessment by Monotherapy Products, H1 2014 45
Number of Products by Top 10 Target, H1 2014 47
Number of Products by Stage and Top 10 Target, H1 2014 48
Number of Products by Top 10 Mechanism of Action, H1 2014 50
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 51
Number of Products by Top 10 Route of Administration, H1 2014 53
Number of Products by Stage and Top 10 Route of Administration, H1 2014 54
Number of Products by Top 10 Molecule Type, H1 2014 55
Number of Products by Stage and Top 10 Molecule Type, H1 2014 56

Explore Report on Pharmaceuticals & Therapeutic Market.

Contact [email protected] / Call +1 888 391 5441 for further information on “Chronic Heart Failure – Pipeline Review, H1 2014” report OR for any other market research and intelligence needs you may have for your business.